The spread of extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-E) is leading to increased carbapenem consumption. Alternatives to carbapenems need to be investigated. We investigated whether β-lactam/β-lactamase inhibitor (BLBLI) combinations are as effective as carbapenems in the treatment of bloodstream infections (BSI) due to ESBL-E. A multinational, retrospective cohort study was performed. Patients with monomicrobial BSI due to ESBL-E were studied; specific criteria were applied for inclusion of patients in the empirical-therapy (ET) cohort (ETC; 365 patients), targeted-therapy (TT) cohort (TTC; 601 patients), and global cohort (GC; 627 patients). The main outcome variables were cure/improvement rate at day 14 and all-cause 30-day mortality. Multivariate analysis, propensity scores (PS), and sensitivity analyses were used to control for confounding. The cure/improvement rates with BLBLIs and carbapenems were 80.0% and 78.9% in the ETC and 90.2% and 85.5% in the TTC, respectively. The 30-day mortality rates were 17.6% and 20% in the ETC and 9.8% and 13.9% in the TTC, respectively. The adjusted odds ratio (OR) (95% confidence interval [CI]) values for cure/improvement rate with ET with BLBLIs were 1.37 (0.69 to 2.76); for TT, they were 1.61 (0.58 to 4.86). Regarding 30-day mortality, the adjusted OR (95% CI) values were 0.55 (0.25 to 1.18) for ET and 0.59 (0.19 to 1.71) for TT. The results were consistent in all subgroups studied, in a stratified analysis according to quartiles of PS, in PS-matched cases, and in the GC. BLBLIs, if active in vitro, appear to be as effective as carbapenems for ET and TT of BSI due to ESLB-E regardless of the source and specific species. These data may help to avoid the overuse of carbapenems. (This study has been registered at ClinicalTrials.gov under registration no. NCT01764490.)

Gutiérrez Gutiérrez, B., Pérez Galera, S., Salamanca, E., De Cueto, M., Calbo, E., Almirante, B., Viale, P., Oliver, A., Pintado, V., Gasch, O., Martínez Martínez, L., Pitout, J., Akova, M., Peña, C., Molina, J., Hernández, A., Venditti, M., Prim, N., Origüen, J., Bou, G., Tacconelli, E., Tumbarello, M., Hamprecht, A., Giamarellou, H., Almela, M., Pérez, F., Schwaber, M. J., Bermejo, J., Lowman, W., Hsueh, P. R., Mora Rillo, M., Natera, C., Souli, M., Bonomo, R. A., Carmeli, Y., Paterson, D. L., Pascual, A., Rodríguez Baño, J., Gálvez, J., Del Toro, M. D., Retamar, P., Falcone, M., Russo, A., Daikos, G., Karaiskos, I., Trecarichi, E. M., Losito, A. R., Paterson, D. L., García Vázquez, E., Gómez, J., Roilides, E., Iosifidis, E., Doi, Y., Tuon, F. F., Navarro, F., Mirelis, B., San Juan, R., Fernández Ruiz, M., Larrosa, N., Puig, M., Cisneros, J. M., González, V., Rucci, V., Ruiz De Gopegui, E., Marinescu, C. I., Fariñas, M. C., Cano, M. E., Gozalo, M., Paño Pardo, J. R., Navarro San Francisco, C., Gómez Zorrilla, S., Tubau, F., Pournaras, S., Tsakris, A., Zarkotou, O., Azap, Ö. K., Antoniadou, A., Poulakou, G., Virmani, D., Torre Cisneros, J., Pérez Nadales, E., Gracia Ahulfinger, I., Helvaci, Ö., Sahin, A. O., Cantón, R., Ruiz, P., Bartoletti, M., Giannella, M., Riemenschneider, F., Badia, C., Xercavins, M., Fontanals, D., Jové, E., A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing enterobacteriaceae, <<ANTIMICROBIAL AGENTS AND CHEMOTHERAPY>>, 2016; 60 (7): 4159-4169. [doi:10.1128/AAC.00365-16] [http://hdl.handle.net/10807/92370]

A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing enterobacteriaceae

German; Tacconelli;Evelina; Tumbarello;I.; Trecarichi;Enrico Maria; Losito;
2016

Abstract

The spread of extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-E) is leading to increased carbapenem consumption. Alternatives to carbapenems need to be investigated. We investigated whether β-lactam/β-lactamase inhibitor (BLBLI) combinations are as effective as carbapenems in the treatment of bloodstream infections (BSI) due to ESBL-E. A multinational, retrospective cohort study was performed. Patients with monomicrobial BSI due to ESBL-E were studied; specific criteria were applied for inclusion of patients in the empirical-therapy (ET) cohort (ETC; 365 patients), targeted-therapy (TT) cohort (TTC; 601 patients), and global cohort (GC; 627 patients). The main outcome variables were cure/improvement rate at day 14 and all-cause 30-day mortality. Multivariate analysis, propensity scores (PS), and sensitivity analyses were used to control for confounding. The cure/improvement rates with BLBLIs and carbapenems were 80.0% and 78.9% in the ETC and 90.2% and 85.5% in the TTC, respectively. The 30-day mortality rates were 17.6% and 20% in the ETC and 9.8% and 13.9% in the TTC, respectively. The adjusted odds ratio (OR) (95% confidence interval [CI]) values for cure/improvement rate with ET with BLBLIs were 1.37 (0.69 to 2.76); for TT, they were 1.61 (0.58 to 4.86). Regarding 30-day mortality, the adjusted OR (95% CI) values were 0.55 (0.25 to 1.18) for ET and 0.59 (0.19 to 1.71) for TT. The results were consistent in all subgroups studied, in a stratified analysis according to quartiles of PS, in PS-matched cases, and in the GC. BLBLIs, if active in vitro, appear to be as effective as carbapenems for ET and TT of BSI due to ESLB-E regardless of the source and specific species. These data may help to avoid the overuse of carbapenems. (This study has been registered at ClinicalTrials.gov under registration no. NCT01764490.)
Inglese
Gutiérrez Gutiérrez, B., Pérez Galera, S., Salamanca, E., De Cueto, M., Calbo, E., Almirante, B., Viale, P., Oliver, A., Pintado, V., Gasch, O., Martínez Martínez, L., Pitout, J., Akova, M., Peña, C., Molina, J., Hernández, A., Venditti, M., Prim, N., Origüen, J., Bou, G., Tacconelli, E., Tumbarello, M., Hamprecht, A., Giamarellou, H., Almela, M., Pérez, F., Schwaber, M. J., Bermejo, J., Lowman, W., Hsueh, P. R., Mora Rillo, M., Natera, C., Souli, M., Bonomo, R. A., Carmeli, Y., Paterson, D. L., Pascual, A., Rodríguez Baño, J., Gálvez, J., Del Toro, M. D., Retamar, P., Falcone, M., Russo, A., Daikos, G., Karaiskos, I., Trecarichi, E. M., Losito, A. R., Paterson, D. L., García Vázquez, E., Gómez, J., Roilides, E., Iosifidis, E., Doi, Y., Tuon, F. F., Navarro, F., Mirelis, B., San Juan, R., Fernández Ruiz, M., Larrosa, N., Puig, M., Cisneros, J. M., González, V., Rucci, V., Ruiz De Gopegui, E., Marinescu, C. I., Fariñas, M. C., Cano, M. E., Gozalo, M., Paño Pardo, J. R., Navarro San Francisco, C., Gómez Zorrilla, S., Tubau, F., Pournaras, S., Tsakris, A., Zarkotou, O., Azap, Ö. K., Antoniadou, A., Poulakou, G., Virmani, D., Torre Cisneros, J., Pérez Nadales, E., Gracia Ahulfinger, I., Helvaci, Ö., Sahin, A. O., Cantón, R., Ruiz, P., Bartoletti, M., Giannella, M., Riemenschneider, F., Badia, C., Xercavins, M., Fontanals, D., Jové, E., A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing enterobacteriaceae, <<ANTIMICROBIAL AGENTS AND CHEMOTHERAPY>>, 2016; 60 (7): 4159-4169. [doi:10.1128/AAC.00365-16] [http://hdl.handle.net/10807/92370]
File in questo prodotto:
File Dimensione Formato  
92370.pdf

non disponibili

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 820.95 kB
Formato Unknown
820.95 kB Unknown   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/92370
Citazioni
  • ???jsp.display-item.citation.pmc??? 43
  • Scopus 110
  • ???jsp.display-item.citation.isi??? 233
social impact